vatalanib has been researched along with Allodynia in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bates, DO; Donaldson, LF; Drake, RA; Hulse, RP | 1 |
| Dawson, J; Esser, R; Grosios, K; Raychaudhuri, A; Wood, J | 1 |
2 other study(ies) available for vatalanib and Allodynia
| Article | Year |
|---|---|
The control of alternative splicing by SRSF1 in myelinated afferents contributes to the development of neuropathic pain.
Topics: Alternative Splicing; Animals; Antibodies; Disease Models, Animal; Functional Laterality; Hyperalgesia; Male; Myelin Sheath; Nerve Fibers, Myelinated; Neuralgia; Pain Measurement; Phthalazines; Protein Kinase Inhibitors; Pyridines; Rats; Rats, Wistar; Sensory Receptor Cells; Serine-Arginine Splicing Factors; Spinal Cord; Time Factors; Vascular Endothelial Growth Factor A; Vesicular Glutamate Transport Protein 1 | 2016 |
Angiogenesis inhibition by the novel VEGF receptor tyrosine kinase inhibitor, PTK787/ZK222584, causes significant anti-arthritic effects in models of rheumatoid arthritis.
Topics: Angiogenesis Inhibitors; Animals; Arthritis, Rheumatoid; Collagen; Female; Hyperalgesia; Male; Mice; Mice, Inbred DBA; Phthalazines; Pyridines; Rats; Receptors, Vascular Endothelial Growth Factor | 2004 |